A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers

Table 2 Clinical details of human breast tumors utilized in this study

Breast tumor sample set: Origin	Set A: DBCG82 b/c	Set C: MDACC
Patient number	128	95
Tumor subtype
Hormone receptor (HR)-positive	42 (LumA), 27 (LumB), 17 (normal-like)	64
HER2-positive	18 (erbB2)	10
Triple (receptor)-negative	24 (basal)	21
Stage
Unknown	0	0
Ductal carcinoma in situ (DCIS)	0	3
1	1	17
2	63	46
3	64	22
4	0	7
Grade
1	19	6
2	52	38
3	30	49
Unknown	27	2
Adjuvant treatment
Tamoxifen	77	19
Aromatase inhibitor	0	38
Cytotoxic chemotherapy	51 (CMF)	65 (anthracycline and/or taxane)
Trastuzumab	0	1

In the Danish DBCG82 b and c breast cancer studies (Set A), premenopausal women with high-risk breast cancer were randomized to receive radiation therapy plus cyclophosphamide, methotrexate, and fluorouracil (CMF) or to CMF chemotherapy alone, and postmenopausal women with high-risk breast cancer were randomized to receive radiation therapy plus tamoxifen (30 mg daily for 1 year) or tamoxifen alone (PMID: 10335782)
CMF cyclophosphamide, methotrexate, and fluorouracil, Lum luminal, MDACC M. D. Anderson Cancer Center

ISSN: 1559-0275